-
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner October 10th, 2019, Bangkok, Thailand — Today, Red Herring announced its Top 100 Asia award winners in recognition of the leading private companies from the region, celebrating these startups’ innovations and technologies across their respective industries. Red Herring Top 100 Asia enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1000 privately financed companies each year in the Asia. Since 1996, ...Oct. 15. 2019 -
EOFLOW Chosen as Company of the Year
EOFLOW made it to the 'Top 10 Diabetes Care Solutions Providers - 2019' list and was chosen as the Company of the Year by Medtech Outlook magazine (see the attachment for a reprint). One can read more about it at: https://diabetes-care.medicaltechoutlook.com/vendors/top-diabetes-care-companies.htmlOct. 07. 2019 -
Menarini Diagnostics & EOFlow sign a long term business agreement
EOFlow Co., Ltd. and A. Menarini Diagnostics S.r.l. Enter Commercial Agreement for International Distribution of Innovative Insulin Patch Pump Seoul, South Korea and Florence, Italy 17 September 2019 – EOFlow Co., Ltd., developer of novel wearable drug delivery solutions, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, today announced a partnership to commercialize the Insulin Patch Pump product developed by EOFlow Co., Ltd. “We are very pleased and excited to work with A. Menarini Diagno...Sep. 17. 2019 -
EOFLOW Receives Breakthrough Device Designation from FDA
EOFlow Receives FDA Breakthrough Device Designation on its Integrated Wearable Automated Insulin Delivery System SAN JOSE, USA and SEOUL, South Korea, March 14, 2019 EOFLOW CO., Ltd., an emerging medical device company with offices in Seoul, South Korea and San Jose, California, announced today that its closed loop Automated Insulin Delivery /Artificial Pancreas Device (AID/AP), the EOPancreas System, has received Breakthrough Device Designation by the U.S. Food and Drug Administration. The EOPancreas System is designed to pr...Mar. 14. 2019 -
EOFLOW awarded a government grant
EOFLOW is awarded a government R&D grant for developing a wearable drug delivery solution.Apr. 05. 2015 -
EOFLOW relocates to a new facility
EOFLOW relocates to a new facility in the City of Seongnam, a southern suburb of Seoul which hosts more technology start-up companies than any other place in Korea.Feb. 23. 2015 -
EOFLOW exhibits at EASD 2014, Vienna
EOFLOW introduces its conceptual prototype of EOPatch wearable disposable insulin delivery product at a business partner’s booth at the 50th EASD (European Association for the Study of Diabetes) Annual Meeting held in Vienna, Austria on 9/15-19. This is the first time ever that EOPatch is displayed at a public event outside of Korea.Sep. 01. 2014 -
EOFLOW awarded a government grant
EOFLOW is awarded a government R&D grant for developing a new pumping system. If the development is successful, the world can enjoy a highly reliable and accurate micro-pumping system at very affordable price ranges.Sep. 25. 2013 -
EOFLOW opens a new world in drug pumping
EOFLOW Co., Ltd. is founded in the Business Incubation Center in Sogang University in Seoul, Korea. The company will be working on commercializing a new pumping technology that promises to provide a small, reliable, accurate, and low cost drug delivery solution.Sep. 01. 2011
Healthcare Innovation Park #H2102 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
